ASH 2021 | Safety and efficacy of CC-99282 in the treatment of R/R NHL
Loretta Nastoupil
• 12 Dec 2021
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, shares some insights into the first results from a Phase I study investigating the use of CC-99282, a next-generation agent that induces targeted degradation of Ikaros/Aiolos transcription factors, in the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NCT03930953). Dr Nastoupil highlights the benefits of current treatment options such as lenalidomide and compares this to the use of CC-99282, including cytotoxicity, activity, and response rates of patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
